Cardio Diagnostics Holdings, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Cardio Diagnostics Holdings, Inc. (CDIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-13
- Cardio Diagnostics Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 0.30%, a 95.24% decline from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 6.30%, a 133.33% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 2.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | 0.30% 10-K · filed 2026-03-13 |
| 2024-12-31 | 6.30% 10-K · filed 2026-03-13 |
| 2023-12-31 | 2.70% 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |